These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 31404822

  • 1. PCSK9 inhibition and inflammation: A narrative review.
    Ruscica M, Tokgözoğlu L, Corsini A, Sirtori CR.
    Atherosclerosis; 2019 Sep; 288():146-155. PubMed ID: 31404822
    [Abstract] [Full Text] [Related]

  • 2. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
    Pradhan AD, Aday AW, Rose LM, Ridker PM.
    Circulation; 2018 Jul 10; 138(2):141-149. PubMed ID: 29716940
    [Abstract] [Full Text] [Related]

  • 3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K, Sharma M, Ferdinand KC.
    Nutr Metab Cardiovasc Dis; 2016 Oct 10; 26(10):853-62. PubMed ID: 27352986
    [Abstract] [Full Text] [Related]

  • 4. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA, Giugliano RP, Leiter LA, Verma S, Park JG, Sever PS, Lira Pineda A, Honarpour N, Wang H, Murphy SA, Keech A, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jul 10; 138(2):131-140. PubMed ID: 29530884
    [Abstract] [Full Text] [Related]

  • 5. Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.
    Del Pinto R, Grassi D, Properzi G, Desideri G, Ferri C.
    High Blood Press Cardiovasc Prev; 2019 Jun 10; 26(3):199-207. PubMed ID: 31236902
    [Abstract] [Full Text] [Related]

  • 6. PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.
    Board C, Kelly MS, Shapiro MD, Dixon DL.
    J Cardiovasc Pharmacol; 2020 May 10; 75(5):410-420. PubMed ID: 32379108
    [Abstract] [Full Text] [Related]

  • 7. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V.
    Circulation; 2016 Nov 29; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract] [Full Text] [Related]

  • 8. PCSK9 inhibitors: clinical evidence and implementation.
    Sabatine MS.
    Nat Rev Cardiol; 2019 Mar 29; 16(3):155-165. PubMed ID: 30420622
    [Abstract] [Full Text] [Related]

  • 9. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
    Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP.
    Atherosclerosis; 2019 Sep 29; 288():85-93. PubMed ID: 31349086
    [Abstract] [Full Text] [Related]

  • 10. PCSK9 and inflammation: a review of experimental and clinical evidence.
    Momtazi-Borojeni AA, Sabouri-Rad S, Gotto AM, Pirro M, Banach M, Awan Z, Barreto GE, Sahebkar A.
    Eur Heart J Cardiovasc Pharmacother; 2019 Oct 01; 5(4):237-245. PubMed ID: 31236571
    [Abstract] [Full Text] [Related]

  • 11. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
    Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP.
    Atherosclerosis; 2019 Sep 01; 288():194-202. PubMed ID: 31253441
    [Abstract] [Full Text] [Related]

  • 12. PCSK9 inhibition for LDL lowering and beyond - implications for patients with peripheral artery disease.
    Gebauer K, Reinecke H.
    Vasa; 2018 Apr 01; 47(3):165-176. PubMed ID: 29412075
    [Abstract] [Full Text] [Related]

  • 13. Alirocumab as add-on therapy to statins: current evidence and clinical potential.
    Auer J, Berent R.
    Ther Adv Cardiovasc Dis; 2018 Jul 01; 12(7):191-202. PubMed ID: 29792380
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
    Zenti MG, Altomari A, Lupo MG, Botta M, Bonora E, Corsini A, Ruscica M, Ferri N.
    Eur J Prev Cardiol; 2018 Nov 01; 25(17):1843-1851. PubMed ID: 30058841
    [Abstract] [Full Text] [Related]

  • 16. PCSK9 inhibition 2018: riding a new wave of coronary prevention.
    Ward NC, Page MM, Watts GF.
    Clin Sci (Lond); 2019 Jan 31; 133(2):205-224. PubMed ID: 30670671
    [Abstract] [Full Text] [Related]

  • 17. How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors.
    Cybulska B, Kłosiewicz-Latoszek L, Penson PE, Nabavi SM, Lavie CJ, Banach M, International Lipid Expert Panel (ILEP).
    Prog Cardiovasc Dis; 2021 Jan 31; 67():65-74. PubMed ID: 33383060
    [Abstract] [Full Text] [Related]

  • 18. Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.
    Schwartz GG, Steg PG, Szarek M, Bittner VA, Diaz R, Goodman SG, Kim YU, Jukema JW, Pordy R, Roe MT, White HD, Bhatt DL, ODYSSEY OUTCOMES Committees and Investigators*.
    Circulation; 2020 May 19; 141(20):1608-1617. PubMed ID: 32223446
    [Abstract] [Full Text] [Related]

  • 19. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
    Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS.
    Circulation; 2018 Jan 23; 137(4):338-350. PubMed ID: 29133605
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.